Cytokinetics rises as Edgewise posts mid-stage trial data for heart disorder therapy
Source: SeekingAlpha
2025-04-02 08:17:19 ET
More on Edgewise Therapeutics
- Edgewise Therapeutics: More Expensive Now, But Much More Derisked
- Edgewise rated as a new Hold at Stifel on a balanced risk-reward setup
- Seeking Alpha’s Quant Rating on Edgewise Therapeutics
- Historical earnings data for Edgewise Therapeutics
- Financial information for Edgewise Therapeutics
Read the full article on Seeking Alpha
For further details see:
Cytokinetics rises as Edgewise posts mid-stage trial data for heart disorder therapy
Edgewise Therapeutics Inc.
NASDAQ: EWTX
EWTX Trading
-3.65% G/L:
$37.63 Last:
906,324 Volume:
$40 Open:
EWTX Latest News
June 01, 2026 08:30:00 am
Edgewise Therapeutics Announces Sale of Sevasemten for Up to $2.65 Billion, Strengthening Balance Sheet and Centering Company Focus on Cardiovascular Pipeline
EWTX Stock Data
$3,280,862,770
54,628,112
N/A
52
N/A
Biotechnology & Life Sciences
Healthcare
US
Boulder
